ENGERIX-B PAEDIATRIC DOSE hepatitis B surface antigen recombinant (yeast) 10 microgram/0.5mL injection syringe Австралия - английски - Department of Health (Therapeutic Goods Administration)

engerix-b paediatric dose hepatitis b surface antigen recombinant (yeast) 10 microgram/0.5ml injection syringe

glaxosmithkline australia pty ltd - hepatitis b surface antigen recombinant, quantity: 10 microgram - injection, suspension - excipient ingredients: dibasic sodium phosphate dihydrate; aluminium hydroxide hydrate; sodium chloride; monobasic sodium phosphate; water for injections - engerix-b is indicated for active immunisation against hepatitis b virus infection. the nh&mrc* recommend all infants, young children and unvaccinated adolescents receive a primary course of immunisation against hepatitis b. the nh&mrc also recommends immunisation for persons who are at substantial risk and have been demonstrated or judged to be susceptible to the hepatitis b virus. groups identified at increased risk of acquiring hbv infection include: infants born to carrier (hbsag-positive) mothers; individuals for whom post-exposure prophylaxis for hepatitis b is indicated; household contacts (other than sexual partners) of acute and chronic hepatitis b cases and carriers; susceptible sexual contacts. risk occurs in susceptible (anti-hbs negative) partners of hbv carriers and patients with acute hepatitis b; susceptible clients of std (sexually transmitted disease) clinics, and sexually active men who have sex with men are also at increased risk of infection; injecting drug users; haemodialysis patients, hiv-positive individuals and other immunosuppressed adults; patients receiving certain blood products especially patients with clotting disorders receiving blood product concentrates; individuals with chronic liver disease and / or hepatitis c; staff and residents of facilities for the intellectually disabled, including both residential and non-residential care of this group; liver transplant recipients. such individuals should be vaccinated prior to transplantation if seronegative for hepatitis b, as they may be at increased risk of infection from the transplanted organ; staff and inmates of long term correctional facilities; health care workers, dentists, embalmers, tattooists and body-piercers. all staff directly involved in patient care, embalming, or in the handling of human blood or tissue should be vaccinated; individuals adopting children from overseas. these children should be tested for hepatitis b, and if hbsag positive, members of the adoptive family should be vaccinated; others in whom vaccination may be justified include police, members of the armed forces and emergency services staff, depending on the risks of exposure associated with assigned duties. long term travellers to regions of high endemicity, and those residing for some time in such regions who may anticipate close personal contact with local residents, should be vaccinated. short-term tourists or business travellers are at very little risk of hepatitis b, provided they avoid exposure through sexual contact, injecting drug use, tattooing or body piercing. although the risk of hepatitis b infection in contact sports is low, immunisation of those involved should not be discouraged. as the risk in australian schools is very low, vaccination of classroom contacts is seldom indicated. nevertheless, vaccination of school children and adolescents should be encouraged; as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection, it can be expected that hepatitis d will also be prevented by vaccination with engerix-b. the vaccine will not protect against infection caused by hepatitis a, hepatitis c and hepatitis e viruses, and other pathogens known to infect the liver.

Influvac Sub-unit, suspension for injection (influenza vaccine, surface antigen, inactivated) Ирландия - английски - HPRA (Health Products Regulatory Authority)

influvac sub-unit, suspension for injection (influenza vaccine, surface antigen, inactivated)

mylan ire healthcare limited - a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/2570/2019, ivr-215) ; a/cambodia/e0826360/2020 (h3n2)-like strain (a/cambodia/e0826360/2020, ivr-224); b/washington/02/2019-like strain (b/washington/02/2019, wild type) - suspension for injection in pre-filled syringe - 0.5 microgram(s) - influenza vaccines; influenza, inactivated, split virus or surface antigen

BETADINE SORE THROAT GARGLE povidone-iodine 75mg/mL mouthwash bottle Австралия - английски - Department of Health (Therapeutic Goods Administration)

betadine sore throat gargle povidone-iodine 75mg/ml mouthwash bottle

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - povidone-iodine, quantity: 75 mg/ml (equivalent: iodine, qty 7.5 mg/ml) - mouthwash - excipient ingredients: citric acid monohydrate; ethanol; glycerol; dibasic sodium phosphate dodecahydrate; methyl salicylate; sodium hydroxide; menthol; purified water - antibacterial for use as an aid in the treatment of sore throats.

ORKAMBI 100/125 lumacaftor/ivacaftor 100 mg/125 mg film-coated tablet blister pack Австралия - английски - Department of Health (Therapeutic Goods Administration)

orkambi 100/125 lumacaftor/ivacaftor 100 mg/125 mg film-coated tablet blister pack

vertex pharmaceuticals australia pty ltd - ivacaftor, quantity: 125 mg; lumacaftor, quantity: 100 mg - tablet, film coated - excipient ingredients: hypromellose acetate succinate; sodium lauryl sulfate; microcrystalline cellulose; povidone; magnesium stearate; croscarmellose sodium; titanium dioxide; purified water; purified talc; brilliant blue fcf aluminium lake; polyvinyl alcohol; macrogol 3350; cochineal; indigo carmine aluminium lake; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Vildagliptin Pharmacare 50 mg tablets Малта - английски - Malta Medicines Authority

vildagliptin pharmacare 50 mg tablets

pharmacare srl via marghera, 29 20149, milan, italy - tablet - vildagliptin 50 mg - drugs used in diabetes

Pazopanib Pharmacare 200 mg film-coated tablets Малта - английски - Malta Medicines Authority

pazopanib pharmacare 200 mg film-coated tablets

pharmacare premium limited hhf 003 halfar industrial estate birzebbugia bbg 3000, malta - film-coated tablet - pazopanib 200 mg - antineoplastic agents